Elsevier

European Journal of Cancer

Volume 42, Issue 15, October 2006, Pages 2492-2498
European Journal of Cancer

Numerous high-risk epithelial lesions in familial breast cancer

https://doi.org/10.1016/j.ejca.2006.05.027Get rights and content

Abstract

Purpose

To assess the occurrence of high-risk epithelial lesions in women of breast cancer families with and without a BRCA mutation.

Patients and methods

Prospective study of women at very high risk of breast cancer undergoing prophylactic mastectomy (68 BRCA1 mutation carriers, 14 BRCA2 mutation carriers and 24 non-BRCA mutation carriers).

Results

The prevalence of high-risk lesions is equal in women with a BRCA1 or a BRCA2 mutation, but is higher in non-BRCA mutation carriers: all lesions 43% versus 71% (p = 0.02), atypical lobular hyperplasia 26% versus 67% (p = 0.001), atypical ductal hyperplasia 17% versus 42% (p = 0.01), lobular carcinoma-in situ 15% versus 29% (p = 0.10) and ductal carcinoma-in situ 9% versus 17% (p = 0.25). The presence of high-risk lesions is related to absence of a BRCA mutation and to age over 40 years.

Conclusion

Women with an autosomal dominant family history for breast cancer, with and without a BRCA mutation are prone to develop high-risk epithelial lesions, especially over 40 years.

Introduction

Little is known about the early stages of breast cancer development in women with a strong family history. This applies equally to those testing negative for a BRCA mutation and to those carrying a BRCA1 or a BRCA2 mutation. There might be differences in breast cancer development between BRCA1 and BRCA2 mutation carriers because the features of fully developed invasive breast cancers from BRCA1 and BRCA2 mutation carriers are different.1, 2, 3 Women with hereditary predisposition to breast cancer are prone to develop epithelial lesions that indicate a high risk of subsequent invasive breast cancer.4, 5, 6 These high-risk lesions include atypical lobular hyperplasia (ALH), atypical ductal hyperplasia (ADH), lobular carcinoma-in situ (LCIS) and ductal carcinoma-in situ (DCIS).4, 7

The options for women with a deleterious germline mutation in BRCA1 or BRCA2 to handle their high risk are either regular surveillance or prophylactic mastectomy. Bilateral prophylactic mastectomy in healthy women with a BRCA mutation is associated with a 90% reduction in breast cancer incidence.8, 9 When applied at young age, around or before the age of 40 years, this may lead to a significant survival advantage.10 This procedure is much less accepted for women who appeared to be negative for a BRCA mutation even though they have an apparent autosomal dominant family history for breast cancer.11, 12, 13, 14 Especially women with breast cancer at young age and a strong family history but without a BRCA mutation may want to opt for contralateral prophylactic mastectomy. While cancer-free survival is the ultimate test of effectiveness, a first indication may be gleaned from examining mastectomy specimens.

Information is lacking on whether the prevalence of high-risk lesions differs between women with and without a BRCA mutation. In a previous study by our group, of women at high hereditary risk of breast cancer, the prevalence of a BRCA mutation was lower in the group with high-risk lesions compared to the group without high-risk lesions.4 At that time the group that was tested negative for a mutation was not strictly defined and the groups with a BRCA1 or a BRCA2 mutation were too small to be studied separately. In the present study, we investigated the differences in prevalence of high-risk epithelial lesions in women with an exceptionally strong family history for breast cancer with and without a BRCA mutation, who chose for prophylactic mastectomy because of their high risk for breast cancer. These results may be relevant for breast cancer prevention in women with an autosomal dominant family history for breast cancer.

Section snippets

Patient characteristics

Women at high hereditary risk of breast cancer, who underwent prophylactic mastectomy between 1989 and 2004 with and without previous breast cancer, were included. In case a woman had previous breast cancer, prophylactic mastectomy of the contralateral breast was performed. All women had extensive genetic counseling and were shown to have a strong family history for breast cancer, often in combination with ovarian cancer, suggestive for autosomal dominant transmission of the disease, occurring

Histological findings in women with a BRCA1 or a BRCA2 mutation

Eighty-two patients with a deleterious BRCA mutation underwent prophylactic mastectomy (68 BRCA1 mutation carriers and 14 BRCA2 mutation carriers). The total prevalence of all high-risk lesions in BRCA1 and BRCA2 mutation carriers was 44% versus 36% (p = 0.56), with ALH in 26% versus 21% (p = 0.69), ADH in 18% versus 14% (p = 0.70), LCIS in 16% versus 7% (p = 0.38) and DCIS in 9% versus 7% (p = 0.83), respectively.

Risk factors for breast carcinoma were documented at the time of mastectomy. The youngest

Discussion

We here show that women with an autosomal dominant family history for breast cancer that is not caused by a BRCA1 or BRCA2 mutation have an even higher prevalence of epithelial high-risk lesions than mutation carriers. Furthermore, the presence of high-risk lesions is associated with age; especially at age over 40 years a large number of women with and without a BRCA mutation have epithelial high-risk lesions. These epithelial lesions may predict the occurrence of subsequent invasive breast

Conflict of interest statement

None declared.

Acknowledgement

Prof. Dr. J.H. van Krieken, pathologist, generously contributed comments on the study.

References (36)

  • N.D. Kauff et al.

    Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations

    Cancer

    (2003)
  • H. Meijers-Heijboer et al.

    Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation

    N Engl J Med

    (2001)
  • T.R. Rebbeck et al.

    Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group

    J Clin Oncol

    (2004)
  • M.S. van Roosmalen et al.

    Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy

    J Clin Oncol

    (2002)
  • S.A. Narod et al.

    Prevention and management of hereditary breast cancer

    J Clin Onc

    (2005)
  • K. Goldflam et al.

    Contralateral prophylactic mastectomy. Predictors of significant histologic findings

    Cancer

    (2004)
  • L. Lostumbo et al.

    Prophylactic mastectomy for the prevention of breast cancer

    Cochrane Database Syst Rev.

    (2004)
  • K.A. Metcalfe et al.

    Prophylactic bilateral mastectomy: patterns of practice

    Cancer

    (2002)
  • Cited by (26)

    • Non-BRCA familial breast cancer: review of reported pathology and molecular findings

      2017, Pathology
      Citation Excerpt :

      Family history criteria varied across the studies. For familial clustering of breast cancer cases in which no BRCA1/2 mutation was detected, a number of studies used the term BRCAX or BRCAx to encompass these20–34 while others used descriptive terms like non-BRCA families.23,35–45 There was overlap but no uniformity in how family history was defined, and the level of detail provided varied from none at all (patients referred for BRCA testing, not otherwise specified) to well-defined criteria (Table 3; Supplementary Table 3, Appendix A).

    • Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers

      2014, Breast
      Citation Excerpt :

      It is reasonable to assume that the number of premalignant lesions would have been higher if standardized examination of an increased number of sections had been performed. Previous studies have found either higher or equal numbers of malignant and pre-malignant lesions [4,6,7,17,23–27]. One case of primary breast cancer after RRM occurred during follow-up in our study.

    • Vacuum-assisted closure therapy in the management of patients undergoing vulvectomy

      2012, European Journal of Obstetrics and Gynecology and Reproductive Biology
      Citation Excerpt :

      The aim of our study was to investigate whether systematic postoperative VAC therapy could improve vulvectomy healing. We reviewed medical data from 54 women who underwent radical vulvectomy or wide local vulvectomy [9] with defect volume >40 cm3, inguinal lymphadenectomy and/or sentinel lymph nodes (in case of tumor less than 4 cm) and/or rhomboid, gracilis, gluteal flaps at the “Oscar Lambret” Cancer Center (Lille, France). This was a retrospective comparative non-randomized study.

    • Biology and Management of Lobular Carcinoma in Situ of the Breast (Lobular Neoplasia)

      2009, The Breast: Comprehensive Management of Benign and Malignant Diseases
    • Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer

      2008, European Journal of Surgical Oncology
      Citation Excerpt :

      The quick malignant transformation suggested by Adem et al.,7 and the fact that not all lesions will develop from premalignant to malignant asks for techniques to identify those that are prone to progression. Our findings of occult premalignant/preinvasive epithelial lesions or invasive carcinoma are lower than that reported in some previous series.9,12,29 One explanation for these diverging results may be that their sampling of breast tissues was more extensive than ours.

    View all citing articles on Scopus
    View full text